Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:1569-1576
Published online before print September 17, 2007, doi: 10.1161/CIRCULATIONAHA.107.711606
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
116/14/1569    most recent
CIRCULATIONAHA.107.711606v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhuiyan, Z. A.
Right arrow Articles by Wilde, A. A.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhuiyan, Z. A.
Right arrow Articles by Wilde, A. A.M.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Related Collections
Right arrow Clinical genetics
Right arrow Calcium cycling/excitation-contraction coupling
Right arrow Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2007;116:1569-1576.)
© 2007 American Heart Association, Inc.


Molecular Cardiology

Expanding Spectrum of Human RYR2-Related Disease

New Electrocardiographic, Structural, and Genetic Features

Zahurul A. Bhuiyan, MD, PhD; Maarten P. van den Berg, MD, PhD; J. Peter van Tintelen, MD; Margreet T.E. Bink-Boelkens, MD, PhD; Ans C.P. Wiesfeld, MD, PhD; Marielle Alders, PhD; Alex V. Postma, PhD; Irene van Langen, MD, PhD; Marcel M.A.M. Mannens, PhD; Arthur A.M. Wilde, MD, PhD

From the Department of Clinical Genetics (Z.A.B., M.A., I.v.L., M.M.A.M.M.), and Heart Failure Research Center (A.V.P., A.A.M.W.), Academic Medical Center, University of Amsterdam, The Netherlands; Departments of Cardiology (M.P.v.d.B., A.C.P.W.), Clinical Genetics (J.P.v.T.), and Pediatric Cardiology (M.T.E.B.-B.), University Medical Center, University of Groningen, The Netherlands, and Interuniversity Cardiology Institute of The Netherlands (M.P.v.d.B., A.A.M.W.).

Correspondence to Dr Zahurul A. Bhuiyan, Department of Clinical Genetics, Academic Medical Centre, University of Amsterdam, The Netherlands. E-mail z.a.bhuiyan{at}amc.uva.nl

Received April 26, 2007; accepted July 20, 2007.

Background— Catecholaminergic polymorphic ventricular tachycardia is a disease characterized by ventricular arrhythmias elicited exclusively under adrenergic stress. Additional features include baseline bradycardia and, in some patients, right ventricular fatty displacement. The clinical spectrum is expanded by the 2 families described here.

Methods and Results— Sixteen members from 2 separate families have been clinically evaluated and followed over the last 15 years. In addition to exercise-related ventricular arrhythmias, they showed abnormalities in sinoatrial node function, as well as atrioventricular nodal function, atrial fibrillation, and atrial standstill. Left ventricular dysfunction and dilatation was present in several affected individuals. Linkage analysis mapped the disease phenotype to a 4-cM region on chromosome 1q42-q43. Conventional polymerase chain reaction–based screening did not reveal a mutation in either the Ryanodine receptor 2 gene (RYR2) or ACTN2, the most plausible candidate genes in the region of interest. Multiplex ligation-dependent probe amplification and long-range polymerase chain reaction identified a genomic deletion that involved RYR2 exon-3, segregated in all the affected family members (n=16) in these 2 unlinked families. Further investigation revealed that the genomic deletion occurred in both families as a result of Alu repeat–mediated polymerase slippage.

Conclusions— This is the first report on a large genomic deletion in RYR2, which leads to extended clinical phenotypes (eg, sinoatrial node and atrioventricular node dysfunction, atrial fibrillation, atrial standstill, and dilated cardiomyopathy). These features have not previously been linked to RYR2.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
A. Medeiros-Domingo, Z. A. Bhuiyan, D. J. Tester, N. Hofman, H. Bikker, J. P. van Tintelen, M. M.A.M. Mannens, A. A.M. Wilde, and M. J. Ackerman
The RYR2-Encoded Ryanodine Receptor/Calcium Release Channel in Patients Diagnosed Previously With Either Catecholaminergic Polymorphic Ventricular Tachycardia or Genotype Negative, Exercise-Induced Long QT Syndrome A Comprehensive Open Reading Frame Mutational Analysis.
J. Am. Coll. Cardiol., November 24, 2009; 54(22): 2065 - 2074.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al.
Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'
Europace, July 1, 2009; 11(7): 860 - 885.
[Full Text] [PDF]


Home page
ESC Textbook of Cardiovascular MedicineHome page
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst
CHAPTER 29 Atrial Fibrillation
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]